Navigation Links
Pharmaxis in Medical News

Pharmaxis Announces NDA Filing for Aridol(TM) (Mannitol Bronchial Challenge Test)

.../ -- Pharmaxis, Inc., a wholly owned subsidiary of pharmaxis Ltd (ASX: PXS, Nasdaq: PXSL ), an emerging respi... Brett Charlton MBBS, PhD, Medical Director, pharmaxis Ltd, added, "Aridol is designed to measure bronchi... of elite athletes who are asthmatic. About pharmaxis ...

Pharmaxis to Expand Manufacturing Capacity

...nchitol to approximately 40,000 patients per year. pharmaxis is developing Bronchitol for the treatment of dise...pand initial capacity in a modular fashion. About pharmaxis pharmaxis (ACN 082 811 630) is a pharmaceutical company invo...
Pharmaxis in Medical Technology

ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia

SYDNEY, Australia, Sept. 30 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that a marketing application for the mucus clearing agent, Bronchitol, has been submitted to the Therapeutic Goods Administration (TGA) division of the Austral...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

...Newswire-Asia-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL ) is pleased to announce... averages 1-2% per year. Dr Alan Robertson, pharmaxis Chief Executive Officer said: "We are delighted th...treating cystic fibrosis in Europe and elsewhere. pharmaxis will now move to file a marketing application late...

Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis

...le with cystic fibrosis. Dr Alan Robertson, pharmaxis Chief Executive Officer said: "We are very pleased to announce this major milestone for pharmaxis and look forward to the results of the study with ... Bronchitol in people with cystic fibrosis. pharmaxis has received Orphan Drug Designation and fast trac...

Pharmaxis Announces New Drug Application Submission for Aridol(TM)

...Newswire-Asia-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS, Nasdaq: PXSL ) today announced it had... The NDA application is the vehicle through which pharmaxis formally proposes that the FDA approve a new pharm...es complete and ready to use. Alan Robertson, pharmaxis Chief Executive Officer said: "We are delighted to...

Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins

...ua-PRNewswire-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it h...chitol for cystic fibrosis in the United States. pharmaxis Chief Executive Officer Dr Alan Robertson said: "W...com.au/library/2008_09_04_CF302_Commences.pdf . pharmaxis is developing Bronchitol as a treatment to improve...

12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis

...ua-PRNewswire-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the ...es were a consequence of the underlying disease. pharmaxis CEO Alan Robertson said: "Pharmaxis intends to fil...rmaceutical markets suffer from bronchiectasis and pharmaxis expects Bronchitol to be the first targeted medica...

Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment

...baseline in FEV1 (forced expiratory volume in one second) after 26 weeks. pharmaxis Chief Executive Officer Alan Robertson said: "It is rewarding to reach this...esults helping to shape cystic fibrosis clinical practice in the future." pharmaxis has received Orphan Drug Designation and fast track status from the U.S. Fo...

Bronchitol Cystic Fibrosis Dose Trial Results Positive

...re-FirstCall/ -- Speciality pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced results f...% on 240 mg, +1.5% on 120 mg and -0.6% on 40 mg. pharmaxis Chief Executive Officer Alan Robertson said, "The ...per year during their life, as measured by FEV1. pharmaxis has received Orphan Drug Designation and fast trac...

Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial

... and/or data analyses are acceptable to the FDA. pharmaxis previously agreed on the trial design with the Eur...f a successful shorter trial reported last year. pharmaxis CEO, Alan Robertson, said the company was pleased ...l trial is expected to soon close recruitment.'' pharmaxis is developing Bronchitol as a treatment to improve...

Pharmaxis Establishes Named Patient Program for Bronchitol

... The program will allow patients who are unable to participate in current pharmaxis clinical trials but who are considered by their physician to be suffering f... to medicines in countries where the product is yet to be authorised," said pharmaxis CEO Alan Robertson. "Bronchitol will be made available to people with a c...
Pharmaxis in Biological Technology

New Pharmaxis Board Appointment

SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced the appointment of the U.S. life science investment manager Richard van den Broek to its Board of Directors. Mr van den Broek is founder and managing partner of HSMR Advisor...

New Pharmaxis Board Appointment

SYDNEY, Australia, June 23 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of senior Australian pharmaceutical executive Will Delaat to its board of directors. Mr Delaat has 35 years experience in the global pharmaceutical industry, most re...

Pharmaxis Investor Conference Call

... SYDNEY, July 21 /PRNewswire-Asia/ -- pharmaxis Ltd (ASX: PXS) will release its June 2009 Quarterl...cording of the conference will be available on the pharmaxis website home page approximately 3 hours after the call. CONTACT: pharmaxis Investor Relations Tel: +61-2-9454-7200 ...

Pharmaxis to Voluntarily De-List from Nasdaq

... SYDNEY, July 12 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced a deci...t from the Nasdaq Global Market ("Nasdaq"). pharmaxis has recently completed a review of the demand from...itary Shares ("ADS's") on Nasdaq and the volume of pharmaxis ADS trading in the secondary Nasdaq market. The r...

Pharmaxis Closes Share Purchase Plan

... SYDNEY, June 29 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced it had raised A$7.2 million fro...ximately $7.2 million. Dr Alan Robertson, Chief Executive Officer of pharmaxis said, "We are very encouraged and appreciative of the level of support from...

Pharmaxis Announces Placement of $47 Million and Share Purchase Plan

... SYDNEY, June 3 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS, Nasdaq: PXSL ) today announced that i...acement strengthens the company's balance sheet as pharmaxis moves toward the European and U.S. commercial laun...its product Bronchitol for cystic fibrosis. pharmaxis will issue 20 million new fully paid ordinary shar...

U.S. FDA Accepts Aridol(TM) New Drug Application for Review

... SYDNEY, Australia, May 13 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced it had...e result of the review on 27 December 2009. pharmaxis is seeking approval for Aridol for "the assessment... test available in the U.S. Alan Robertson, pharmaxis Chief Executive Officer said: "We have been greatl...

Pharmaxis Investor Conference Call

... SYDNEY, Australia, April 6 /PRNewswire-Asia/ -- pharmaxis Ltd (AXS: PXS; Nasdaq: PXSL ) will release its M...cording of the conference will be available on the pharmaxis website home page approximately 3 hours after the call. CONTACT: pharmaxis Investor Relations Tel: +61-2-9454-7200 ...

Pharmaxis Appoints French Distributor for Aridol(TM)

... SYDNEY, March 11 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; NASDAQ: PXSL ) is pleased to announce that it has appointed Pr...after market the product to hospital specialists. Dr Alan Robertson, pharmaxis CEO said "We are delighted to announce this agreement and are looking forwa...

Pharmaxis Builds Senior Management Team

...cal Expert for Novartis. Dr Alan Robertson, pharmaxis Chief Executive Officer said: "The appointment of ...ory and pharmacovigilance experience necessary for pharmaxis to bring Bronchitol successfully and rapidly to th...the company's head office in Sydney. About pharmaxis ...
Other Tags
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
(Date:8/28/2015)... ... ... With the goal of furthering music education programs in schools, the “Music With ... in Mendon, IL on May 30th, 2015. Backed once again by Best Drug Rehabilitation, ... school districts of Mendon and its neighboring town of Quincy, IL. Best Drug Rehabilitation’s ...
(Date:8/28/2015)... , ... August 28, 2015 , ... On May 30th, ... joined as sponsor of the “Music With A Mission” benefit concert in Mendon, IL. ... event was to raise money to support music education programs in the underfunded local ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... specialist, Dr. James Strawbridge, gives a new approach on solutions in his new ... with the employer and employees getting together for meaningful group meetings. "This would ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... a low cost. Personalized with practice contact information and logos, Calendars stand alone ... can also incorporate Calendars into seasonal mailings, thank you and welcome communications, and ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
Other Contents